Clinical trials: Tachyarrhythmia, open to volunteers
Ventricular Arrhythmia, Ventricular Tachycardia (V-Tach)
Proton Radiosurgery for the Treatment of Malignant Ventricular Tachyarrhythmias
Ventricular arrhythmias (VAs) are the leading cause of sudden cardiac death (SCD) worldwide. The implantable defibrillator (ICD) increases survival in patients at risk of VA, with data of superiority to antiarrhythmic drugs.
- Trial name
- TOVEL (NCT06769451)
- Testing
- Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Azienda Sanitaria Universitaria Integrata del Trentino
Tachyarrhythmia
Lead Evaluation for Defibrillation and Reliability Post Approval Study
Medtronic is sponsoring the LEADR PAS to provide continuing evaluation and periodic reporting of safety and effectiveness of the OmniaSecure™ defibrillation lead following commercial release.
- Trial name
- LEADR PAS (NCT07005232)
- Testing
- defibrillation lead
- Where
- 97 sites in United States, Austria and 7 more
- Volunteers
- 2,000 people
- Sponsor
- Medtronic
Ventricular Tachycardia
Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial
The objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT…
- Trial name
- DEFT STAR (NCT05594368)
- Testing
- Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)
- Where
- 3 sites in Czechia, Switzerland
- Volunteers
- 15 people
- Sponsor
- University of Zurich
Persistent Atrial Fibrillation
FIH Study of PFLotus in Persistent Atrial Fibrillation
Single-shot pulsed-field ablation (PFA) catheters maximize pulmonary vein isolation (PVI) efficiency but are limited for focal or linear ablation.
- Trial name
- PFLotus- FIH (NCT07301190)
- Testing
- Pulse field ablation with the PFLotus catheter
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Third People's Hospital of Chengdu
Heart Disease, Implantable Cardioverter Defibrillator (ICD)
Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD
This is a pragmatic, two-group, cluster randomized trial designed to compare strategies for the Anti Tachycardia Pacing (ATP)-setting in the ventricular tachyarrhythmias (VT) zone when implanting a new implantable cardioverter…
- Conditions
- Heart Disease, Implantable Cardioverter Defibrillator (ICD), Heart Rhythm Disorders, Ventricular Tachyarrhythmias
- Trial name
- DAN-ATP (NCT07354347)
- Testing
- Burst, Ramp
- Where
- Denmark
- Volunteers
- 3,980 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Atrial Fibrillation (AF)
Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation
This study aims to evaluate whether acupuncture can reduce the recurrence of atrial arrhythmias after catheter ablation in patients with persistent atrial fibrillation.
- Trial name
- NCT07487532
- Testing
- Electroacupuncture, Standard Medical Therapy
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhongshan Hospital
Sudden Cardiac Death
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
The PROTECT-ICD trial is a physician-led, multi-centre randomised controlled trial targeting prevention of sudden cardiac death in patients who have poor cardiac function following a myocardial infarct (MI).
- Trial name
- PROTECT-ICD (NCT03588286)
- Testing
- Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR)
- Where
- 52 sites in United States, Australia and 13 more
- Volunteers
- 1,058 people
- Sponsor
- Western Sydney Local Health District
Shock
Vasoactive Drugs in Intensive Care Unit
The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine.
- Trial name
- NCT02118467
- Testing
- Norepinephrine, Epinephrine, Phenylephrine
- Where
- United States
- Volunteers
- 836 people
- Sponsor
- University of Chicago
Acute Myocardial Infarction (AMI), Asystole
SPIKE FLOW Endocardial Lead Safety and Performance Study
The objective of this study is to assess the safety and performance of the SPIKE FLOW endocardial lead. Primary objectives are to assess: safety in terms of freedom from Serious Adverse Events(SADEs); performance in terms of Mean…
- Conditions
- Acute Myocardial Infarction (AMI), Asystole, Bradycardia, AV Block
- Trial name
- SPIKE FLOW (NCT07820072)
- Testing
- Lead insertion, lead removal
- Where
- 3 sites in Italy
- Volunteers
- 131 people
- Sponsor
- FIAB SpA
Idiopathic Ventricular Fibrillation, Cardiac Arrest, Out-Of-Hospital
MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
A person who has experienced a cardiac arrest with no apparent cause is at risk of having recurrent cardiac arrest. Hence an implantable cardioverter-defibrillator (ICD) is recommended on empirical grounds.
- Trial name
- RIME-IVF (NCT07405229)
- Testing
- Beta-blocker treatment group
- Where
- 2 sites in Denmark
- Volunteers
- 218 people
- Sponsor
- Bo Gregers Winkel
Tachyarrhythmia, Heart Failure
BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs
The CorSky family is BIOTRONIK´s new generation of ICDs. They are the successor devices of the current Acticor/Rivacor family and inherit all iShock/iShock_BC (Ilivia Neo, Intica Neo) implant and programmer software features.
- Trial name
- NCT07360158
- Testing
- CorSky ICD or CRT-D
- Where
- 7 sites in Austria, Czechia and 2 more
- Volunteers
- 151 people
- Sponsor
- Biotronik SE & Co. KG